Comments by "S L" (@sl4983) on "JUST IN: Vivek Ramaswamy Speaks To Reporters After Holding Several Campaign Events In Iowa" video.

  1. Ramaswamy cofounded a biotech company. - Roivant Sciences, and includes Lokavant, which is to mitigate risks in pharmaceutical development. In 2017, Roivant partnered with the private equity arm of Chinese state-owned CITIC Group to form Sinovant. As of 2019, Roivant had over forty investigational drugs in development in fourteen therapeutic areas across its family of companies. In April 2020, Roivant dosed the first patient in a clinical study evaluating gimsilumab in COVID-19 patients for the prevention and treatment of acute respiratory distress syndrome (ARDS). in April, Datavant announced that its technology is being used to create a pro bono COVID-19 research database to help public health and policy researchers combat the pandemic.
    2
  2. He cofounded a biotech company. - Roivant Sciences, and includes Lokavant, which is to mitigate risks in pharmaceutical development. In 2017, Roivant partnered with the private equity arm of Chinese state-owned CITIC Group to form Sinovant. As of 2019, Roivant had over forty investigational drugs in development in fourteen therapeutic areas across its family of companies. In April 2020, Roivant dosed the first patient in a clinical study evaluating gimsilumab in COVID-19 patients for the prevention and treatment of acute respiratory distress syndrome (ARDS). in April, Datavant announced that its technology is being used to create a pro bono COVID-19 research database to help public health and policy researchers combat the pandemic.
    2
  3. He cofounded a biotech company. - Roivant Sciences, and includes Lokavant, which is to mitigate risks in pharmaceutical development. In 2017, Roivant partnered with the private equity arm of Chinese state-owned CITIC Group to form Sinovant. As of 2019, Roivant had over forty investigational drugs in development in fourteen therapeutic areas across its family of companies. In April 2020, Roivant dosed the first patient in a clinical study evaluating gimsilumab in COVID-19 patients for the prevention and treatment of acute respiratory distress syndrome (ARDS). in April, Datavant announced that its technology is being used to create a pro bono COVID-19 research database to help public health and policy researchers combat the pandemic.
    2